Year All2026202520242023 Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea July 23, 2026 PDF Version Read More Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea June 25, 2026 PDF Version Read More Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position March 27, 2026 PDF Version Read More Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research March 25, 2026 PDF Version Read More Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development March 18, 2026 PDF Version Read More ASX Announcements
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea July 23, 2026 PDF Version Read More
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea June 25, 2026 PDF Version Read More
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility June 10, 2026 PDF Version Read More
Incannex Announces Initiation of Research Coverage by Alliance Global Partners June 9, 2026 PDF Version Read More
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea May 14, 2026 PDF Version Read More
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development May 12, 2026 PDF Version Read More
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness April 22, 2026 PDF Version Read More
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position March 27, 2026 PDF Version Read More
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research March 25, 2026 PDF Version Read More
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development March 18, 2026 PDF Version Read More
